Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer’s Disease (AD)
ION269-CS1
Phase 1 other active
Quick answer
Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of ION269 in Participants With Down Syndrome (DS) at Risk for Alzheimer’s Disease (AD) for Alzheimer’s Disease in Individuals with Down Syndrome is a Phase 1 program (other) at IONIS PHARMACEUTICALS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- IONIS PHARMACEUTICALS INC
- Indication
- Alzheimer’s Disease in Individuals with Down Syndrome
- Phase
- Phase 1
- Modality
- other
- Status
- active